title: Novel approaches for the management of patients with Ewing sarcoma.
abstract: The concepts of tailored therapy according to genetic profiling and response based on minimal residual disease evaluation during therapy are attracting increasing interest in modern clinical oncology. Children with acute lymphoblastic leukemia are being stratified to various treatment arms with different intensities according to the genetic characteristics of their leukemia and their response to therapy as measured by real-time polymerase chain reaction. Our ability to quickly identify patients with Ewing sarcoma who have a poor prognosis, and to offer them aggressive therapeutic modalities, such as stem cell transplantation, may result in an improved cure rate. Based on the knowledge gained by gene expression profiling and gene silencing techniques we can expect the emergence of new specific drugs that will target malignant cells without causing damage to normal tissue, resulting in improved cancer therapy.
authors.affiliation: Molecular Oncology, Felsenstein Medical Research Center, Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine, Tel Aviv University, Petah-Tikva, Israel. savigad@post.tan.ac.il
authors.forename: Smadar
authors.initials: S
authors.lastname: Avigad
authors.forename: Isaac
authors.initials: I
authors.lastname: Yaniv
mesh_terms: D018572:Disease-Free Survival; D020868:Gene Silencing; D006801:Humans; D046228:Microarray Analysis; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D011379:Prognosis; D051789:Proto-Oncogene Protein c-fli-1 / Q000235:genetics; D034802:RNA-Binding Protein EWS; D012512:Sarcoma, Ewing / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D033581:Stem Cell Transplantation; D014157:Transcription Factors / Q000235:genetics
chemical_list: C450460:EWS-ERG fusion protein, human; C106031:EWS-FLI fusion protein; D015514:Oncogene Proteins, Fusion; D051789:Proto-Oncogene Protein c-fli-1; D034802:RNA-Binding Protein EWS; D014157:Transcription Factors